导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.51% | 854/4773 |
| 近一周 | -3.99% | 4954/5465 |
| 近一月 | -0.16% | 736/5421 |
| 近一季 | -5.03% | 1940/5231 |
| 近半年 | -8.43% | 3503/4920 |
| 近一年 | 23.92% | 362/4394 |
| 近两年 | 75.07% | 930/2954 |
| 近三年 | 56.97% | 492/2253 |
| 成立以来 | 80.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
10.30% 64/4961 |
-1.24% 3342/5312 |
- - |
- - |
| 2025 | 38.78% 858/4813 |
-0.36% 2216/3635 |
2.76% 1380/4076 |
24.01% 1498/4524 |
9.30% 198/4813 |
| 2024 | 8.74% 1521/3463 |
7.85% 217/2808 |
-1.17% 962/3014 |
9.83% 2664/3129 |
-7.11% 2730/3463 |
| 2023 | -0.48% 456/2656 |
5.13% 824/2280 |
-5.63% 1509/2385 |
3.38% 187/2515 |
-2.97% 563/2655 |
| 2022 | -7.30% 142/2207 |
0.62% 111/1919 |
5.79% 824/2016 |
-8.25% 184/2113 |
-5.07% 1916/2208 |
| 2021 | 38.65% 41/1822 |
3.38% 180/1255 |
9.28% 569/1330 |
31.30% 12/1466 |
-6.52% 1539/1822 |
| 2020 | 38.05% 369/1250 |
-11.99% 867/1028 |
8.25% 827/1067 |
20.93% 46/1164 |
19.83% 68/1184 |
| 2019 | 23.81% 624/1092 |
20.11% 613/754 |
-2.20% 346/804 |
-4.37% 769/850 |
10.22% 154/918 |
| 2018 | -29.86% 458/834 |
- - |
- - |
- - |
-16.03% 622/691 |
| 2017 | 17.92% 214/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.37% 215/605 |
- - |
- - |
- - |
- - |
| 2015 | 1.88% 242/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.29% 177/237 |
- - |
- - |
- - |
- - |
| 2013 | -33.33% 179/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.50% 84/140 |
- - |
- - |
- - |
- - |
| 2011 | -33.13% 98/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安上证商品ETF联接A VS. 长安沪深300非周期A(740101) |